Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence

A Rizzo, M Rosellini, A Marchetti, V Mollica… - …, 2021 - Taylor & Francis
The last three decades have witnessed a revolution in the therapeutic scenario of metastatic
renal cell carcinoma (mRCC), due to the advent of novel agents including tyrosine kinase …
被引用次数：7 相关文章

Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: A critical overview of recent evidence

A Rizzo, M Rosellini, A Marchetti, V Mollica… - …, 2021 - cris.unibo.it
The last three decades have witnessed a revolution in the therapeutic scenario of metastatic
renal cell carcinoma (mRCC), due to the advent of novel agents including tyrosine kinase …

Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence

A Rizzo, M Rosellini, A Marchetti, V Mollica… - …, 2021 - pubmed.ncbi.nlm.nih.gov
The last three decades have witnessed a revolution in the therapeutic scenario of metastatic
renal cell carcinoma (mRCC), due to the advent of novel agents including tyrosine kinase …

Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence.

A Rizzo, M Rosellini, A Marchetti, V Mollica… - Immunotherapy, 2021 - europepmc.org
The last three decades have witnessed a revolution in the therapeutic scenario of metastatic
renal cell carcinoma (mRCC), due to the advent of novel agents including tyrosine kinase …